BAYN.DE
$38.38-0.08 (-0.21%)
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer ...
Recent News
Bayer’s Kerendia Trial Success Opens New Chapter In Kidney Disease Story
Bayer (XTRA:BAYN) reported that its Phase III FIND-CKD trial for Kerendia met its primary endpoint. The study showed a statistically significant benefit in patients with non-diabetic chronic kidney disease. The company plans to pursue regulatory approvals to expand Kerendia’s label beyond its current diabetic CKD indication. Bayer’s Kerendia is already used for patients with chronic kidney disease linked to type 2 diabetes, and this latest Phase III success extends its potential role into...
Health Care Roundup: Market Talk
Find insight on Bayer, Amplifon’s acquisition of GN Store Nord’s hearing-aid business, and more in the latest Market Talks covering the Health Care sector.
Bayer eyes label expansion on Phase III non-diabetic CKD win
If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who have a non-diabetic form of the disease.
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
What’s at stake for Bayer in its Supreme Court showdown?
A key case being heard by the Supreme Court could help the large pharma put its Roundup litigation to rest.